Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-07 10:01 am Purchase |
2025-02-28 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 7,851,098 10.300% |
983,414 (+14.32%) |
Filing History |
| 2024-11-12 10:40 am Purchase |
2024-11-08 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 6,867,684 9.064% |
1,211,762 (+21.42%) |
Filing History |
| 2024-02-14 09:12 am Purchase |
2023-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 5,666,666 7.700% |
766,666 (+15.65%) |
Filing History |
| 2024-02-14 07:43 am Sale |
2023-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
DRIEHAUS CAPITAL MANAGEMENT INC | 4,345,180 5.880% |
-336,617 (-7.19%) |
Filing History |
| 2024-02-09 10:05 am Purchase |
2024-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 5,655,922 7.556% |
965,093 (+20.57%) |
Filing History |
| 2024-02-08 10:03 am Purchase |
2023-12-29 | 13G | Xenon Pharmaceuticals Inc. XENE |
WELLINGTON MANAGEMENT CO LLP | 4,162,654 5.560% |
4,162,654 (New Position) |
Filing History |
| 2023-02-14 4:19 pm Sale |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
Point72 Asset Management, L.P. | 1,178,501 1.900% |
-1,828,637 (-60.81%) |
Filing History |
| 2023-02-14 09:41 am Sale |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 4,900,000 7.800% |
-85,000 (-1.71%) |
Filing History |
| 2023-02-13 8:20 pm Sale |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 1,271,243 2.000% |
-3,034,297 (-70.47%) |
Filing History |
| 2023-02-10 12:10 pm Purchase |
2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
DRIEHAUS CAPITAL MANAGEMENT INC | 4,681,797 7.490% |
1,558,568 (+49.90%) |
Filing History |
| 2023-02-09 12:46 pm Purchase |
2023-02-09 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 4,690,829 7.500% |
780,812 (+19.97%) |
Filing History |
| 2022-03-18 7:18 pm Sale |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 4,305,540 8.200% |
-851,946 (-16.52%) |
Filing History |
| 2022-02-14 4:37 pm Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
Point72 Asset Management, L.P. | 3,007,138 5.800% |
365,885 (+13.85%) |
Filing History |
| 2022-02-14 1:53 pm Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
BIOTECHNOLOGY VALUE FUND L P | 5,157,486 9.990% |
1,658,140 (+47.38%) |
Filing History |
| 2022-02-14 09:14 am Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
DRIEHAUS CAPITAL MANAGEMENT INC | 3,123,229 6.050% |
3,123,229 (New Position) |
Filing History |
| 2022-02-11 5:09 pm Sale |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ORBIMED ADVISORS LLC | 631,000 1.220% |
-1,080,305 (-63.13%) |
Filing History |
| 2022-02-11 10:00 am Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 4,985,000 9.700% |
2,185,000 (+78.04%) |
Filing History |
| 2022-02-10 11:23 am Sale |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ADAGE CAPITAL PARTNERS GP LLC | 665,000 1.290% |
-1,785,000 (-72.86%) |
Filing History |
| 2022-02-09 10:04 am Purchase |
2022-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE |
FMR CORP | 3,910,017 7.579% |
1,284,465 (+48.92%) |
Filing History |
| 2021-10-28 5:24 pm Purchase |
2021-10-27 | 13G | Xenon Pharmaceuticals Inc. XENE |
Point72 Asset Management, L.P. | 2,641,253 5.100% |
2,641,253 (New Position) |
Filing History |